Inovio Receives Authorization from the US FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Re - ACROFAN USA

Inovio Receives Authorization from the US FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Re  ACROFAN USA